SPY330.38-4.12 -1.23%
DIA276.76-2.15 -0.77%
IXIC10,721.53-188.74 -1.73%

SVB Leerink Maintains Outperform on Innate Pharma, Lowers Price Target to $9

SVB Leerink maintains Innate Pharma (NASDAQ:IPHA) with a Outperform and lowers the price target from $10 to $9.

Benzinga · 05/14/2020 11:00

SVB Leerink maintains Innate Pharma (NASDAQ:IPHA) with a Outperform and lowers the price target from $10 to $9.